With the aid of Technicon H6000, platelet counts and platelet aggregations were compared in whole blood samples collected in ethylenedi-aminetetraacetic acid (EDTA) and in heparinized tubes. Although there was no significant difference between platelet count of heparinized and EDTA blood in the ...
The risk of heparin-induced thrombosis can be reduced by minimizing duration of heparin exposure, by using porcine instead of bovine heparin, possibly by monitoring the platelet count, and by early institution of alternate anticoagulation when the syndrome is recognized. It is hoped that a new ...
One of the standard distinctions between type 1 (non-immune) and type 2 (immune-mediated) heparin-induced thrombocytopenia (HIT) is the transience of thrombocytopenia: type 1 HIT is viewed as early-onset and transient thrombocytopenia, with platelet count recovery despite continuing heparin administrat...
Beyond the platelet count: heparin antibodies as independent risk predictors. Am Heart J. 2007;(153):900-906.Stribling WK, Slaughter TF, Houle TT, Sane DC. Beyond the platelet count: heparin antibodies as independent risk predictors. Am Heart J. 2007;153:900 -906....
Heparin(HP)-inducedthrombocytopenia(HIT) is an unusual immune-mediatedadverse drug reactionwith the central paradox being its strong association with thrombosis, despite the role of an anticoagulant (heparin) in causing a fall in platelet count.Platelet factor 4(PF4) bound to endothelial surfaceheparan...
Most patients respond with a marked fall of platelet counts. The relative decrease in platelets is more important than the absolute platelet count. In the absence of any other underlying disease such as sepsis, type II HIT should be considered in the differential diagnosis of patients whose platel...
The most common side effects are hemorrhage (bleeding), thrombocytopenia (decreaseplatelet count), heparin induced thrombocytopenia (HIT), heparin induced thrombocytopenia and thrombosis (HITT), injection site discomfort/irritation, allergyor hypersensitivity type reactions, and increase inliverenzymes. ...
renal arterial thrombosis, skin necrosis, gangrene of the extremities that may lead to amputation, and possibly death. Monitor thrombocytopenia of any degree closely. If the platelet count falls below 100,000/mm3 or if recurrent thrombosis develops, promptly discontinue heparin, evaluate for HIT and...
All patients who are to receive heparin of any sort should have a platelet count on the day of starting treatment. For patients who have been exposed to heparin in the last 100 d, a baseline platelet count and a platelet count 24 h after starting heparin should be obtained. For all ...
Thrombocytopenia: Monitor platelet count during therapy; discontinue heparin if HIT or HITT is suspected. (5.4) • Monitoring: Blood coagulation tests guide therapy for full-dose heparin. Monitor platelet count and hematocrit in all patients receiving heparin. (5.5) • Heparin Resistance: Increase...